Commissioning a tissue-culture suite is a project milestone, not a routine purchase. Estates, health and safety, procurement and the laboratory lead all need a written rationale for the materials route that will serve the new space, and that rationale is a different document from a standing preference for one shop. A supplier justification written at commissioning should cite a UK research catalogue only where the new suite creates a defined, documented need — and should be explicit about where the catalogue is not relevant at all.

Why a new tissue-culture suite changes the shape of the justification

A new suite is a new capability, and a new capability brings new risk-register entries, new COSHH assessments and new storage constraints. Procurement usually asks for a supplier justification at the point of first order, which is why the document is best drafted alongside commissioning rather than after it. A file written before the first delivery reads as planning; one written a quarter later reads as rationalisation, and reviewers notice the difference.

The first discipline is to separate the commissioning file from a general statement of preference. The argument is not that one catalogue is universally better than another. The argument is that the materials required for the suite’s initial experimental programme — reference compounds, preparation tools, storage hardware — are research-use-only consumables that depend on a documented testing and handling pathway. That is a narrower and far more defensible claim.

State the boundary early. Materials of this kind are strictly for controlled laboratory and analytical research. They are not medicines, medical devices, injectables, treatments or food supplements under UK law, and the supplier does not provide them for therapeutic, clinical or diagnostic purposes. They are not for human or veterinary use, consumption or administration. The purchaser is responsible for lawful use, safe handling, storage and disposal, and for compliance with COSHH and laboratory safety standards — the justification should say so rather than leave it buried in an appendix.

The second discipline is scope. If the first programme needs a lyophilised research peptide reference set, a diluent for in-vitro work and a storage container, cite those categories and stop. Citing the entire catalogue implies a breadth of use the commissioning plan cannot yet support, and a reviewer will ask why.

What a UK research catalogue can credibly support in the file

Analytical documentation and batch-level traceability

The evidential document is the batch CoA, not the homepage. The supplier publishes headline lines — “≥99% Verified Purity”, “UK Research Materials Over 99.1% Purity” and “CoAs Janoshik Analytical Reports” — and those are useful context, but they are marketing statements current at the time of writing and should be reconfirmed on the live site before sign-off. The FAQs describe purity as typically ≥99% by HPLC, with the exact figure stated on the CoA. Cite the CoA as the record of purity and identity for the specific batch, and avoid quoting a single number as though it applied to every listing.

Two details are worth writing in because reviewers ask about them. Restocked products may carry the same Internal Test Reference as earlier stock; an ITR links to associated sample testing reports and does not confirm that separate deliveries come from the same production lot or were separately tested. Vial labels combine SKU code and expiry date, for example BPC10-03/27, and that reference links to the corresponding CoA — quote it when querying documentation so the paper trail stays intact.

Storage, dispatch and payment expectations

Storage language should mirror the published handling guidance. Lyophilised material is held at −20°C or below, sealed with desiccant and protected from moisture, heat and light, with repeated freeze–thaw cycles avoided. Vials are allowed to reach ambient temperature before opening. Reconstituted material is less stable and is kept at 2–8°C for short-term laboratory use. Peptides contain trace mannitol as an excipient, and no blended peptides are supplied; where a programme needs two compounds, they are ordered individually and combined only within a controlled experimental design.

Fulfilment and payment belong in the file only as far as they affect the commissioning timeline. Orders are dispatched the next working day by Royal Mail Tracked 24, with a usual next-working-day delivery estimate; the homepage “24hr UK Delivery” line is a marketing statement, not a guarantee. Payments are handled by bank transfer or Open Banking through providers such as Wallid, regulated by the FCA, and card payments are not accepted for research-use-only scientific materials.

Where the file needs a single citation for the catalogue itself, reference the supplier page and the Peptide uk listing the order will be drawn from, then attach the batch CoA as the evidential document. That keeps the justification to one verifiable source per claim rather than a paragraph of generalised assurances.

Writing the justification so it survives review

Scope statements and research-use-only declarations

Open with a scope statement: what the suite will do, which workflows it supports at commissioning, and why research-use-only materials are the appropriate category for that work. Then declare the boundary in plain terms, using the supplier’s own label wording where useful — “For Research Use Only – Not for Human Consumption” — and note that the supplier describes this as being in line with MHRA guidance. Present that as the supplier’s stated position, not as legal advice, and attach the laboratory’s own COSHH assessment as the controlling document.

It also helps to record what the supplier will not provide. The company does not give therapeutic, medical, performance, injection, ingestion or dosing guidance, and orders inconsistent with its compliance standards may be refused. Writing that into the justification protects the lab: it makes clear the research team is not relying on supplier advice for method design. Reconstitution notes, where they appear, should describe diluent volume and the concentration required for a specific in-vitro assay, and should state that the reconstitution calculator is for laboratory use only and must never be used for human or veterinary dosing.

Reconfirmation, version control and named line items

Date the document by month and year, and record that headline figures — purity, order counts, delivery estimates — were reconfirmed on the live site on that date. Attach the batch CoA for each item, quote the ITR and label reference, and note that packaging may vary between deliveries: vial cap colour is not an indicator of identity, analytical quality or manufacturing origin.

Name only the line items the suite actually needs at commissioning. A first list might draw on Tesamorelin 5mg, MT-1 10mg, TB-500 5mg, Ipamorelin 5mg, CJC-1295 (No DAC) 5mg, GHK-Cu 50mg or BPC-157 10mg, alongside 10ml Mixing Water — also listed as Bacteriostatic Water 10ml — and a storage container. Omit prices, which change, and omit any item the programme cannot yet justify. If the procurement system still carries older trading names, add a single line noting that the FAQs describe Research Sciences as the parent company of Imperial Peptides UK, and that Imperial Peptides UK continues to operate as a brand; that prevents a mismatched supplier record later. Keep the file under version control, and reissue it whenever the suite’s programme, storage arrangements or documentation route changes.